From: Endometrial cancer—how many patients could benefit from sentinel lymph node dissection?
Age, years (range) | Median | 63.5 | (28–89) |
Grading, uterus-specimen | G1 | 57 | 52% |
G2 | 30 | 28% | |
G3 | 22 | 20% | |
Histopathological type | |||
Type I | 99 | 91% | |
Type II | 10 | 9% | |
Serous | 6 | ||
Clear cell | 1 | ||
Carcinosarcoma | 3 | ||
Uterine risk factors | Low risk | 53 | 49% |
Intermediate risk | 25 | 23% | |
High-intermediate risk | 13 | 12% | |
High risk | 18 | 17% | |
Nodal involvement | Low risk | 0 | 0% |
Intermediate risk | 3 | 12% | |
High-intermediate risk | 7 | 54% | |
High risk | 11 | 61% | |
Final FIGO stage | IA | 60 | 55% |
IB | 23 | 21% | |
II | 5 | 5% | |
IIIC1 | 10 | 9% | |
IIIC2 | 5 | 5% | |
IIIA | 1 | 1% | |
IVB | 5 | 5% |